UNMC clinical trial evaluating new investigational drug for treatment of COVID

June 11, 2021

Image with file name: 01_06_2021CherylLogan004.jpg

The University of Nebraska Medical Center is involved in a global clinical research trial to evaluate a possible treatment option for non-hospitalized adults with COVID-19.
The medical center is recruiting eligible individuals to assess the safety and efficacy of an oral antiviral drug, Molnupiravir, for the treatment of COVID-19. Molnupiravir aims to block the replication of SARS-CoV-2, the virus that causes COVID-19 to determine if the drug can help reduce COVID-19 symptoms, recovery time, hospitalizations, and death caused by COVID-19.
Diana Florescu, MD, an infectious diseases specialist at Nebraska Medicine and professor in the UNMC Department of Internal Medicine, is leading the clinical trial at UNMC.  "This clinical trial is at the heart of new developments for treatment of COVID-19. We are very happy that UNMC/Nebraska Medicine was chosen as a site for this important work," Dr. Florescu said. 
Eligible study participants will be randomly assigned either to the investigational treatment group or the placebo group. 
The study is seeking people who:
Are at least 19 years of age; 
Have tested positive for COVID-19 in the last 5 days; 
Have had signs and symptoms of COVID-19 for less than 5 days and currently have at least one sign or symptom of COVID-19; 
Have not been hospitalized due to COVID-19; and 
Are at an increased risk of severe illness from COVID-19.
There is no cost for the trial drug or the trial-related medical tests and exams. 
Those interested in participating or learning more about the study can complete a pre-screening survey at: https://unmc.edu/covidclinicalstudy or contact FlorescuResearchTeam@unmc.edu.
We are Nebraska Medicine and UNMCOur mission is to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.
Twitter  |  Facebook  |  Instagram  |  YouTube  |  Flickr